Peroxisomal Disorders Clinical Presentation
- Author: Hoda Z Abdel-Hamid, MD; Chief Editor: Amy Kao, MD more...
Four-group classification by clinical criteria
Peroxisomal disorders also can be classified into 4 groups based on clinical criteria.
Group 1 includes disorders of peroxisome biogenesis (PBD) that share the ZWS phenotype, such as ZWS, a subgroup sharing with ZWS a general loss of all peroxisomal enzymes (ie, NALD, infantile Refsum disease [IRD], hyperpipecolic academia [HPA]); disorders displaying the ZWS phenotype in which peroxisomes are present; those with a deficiency of only 1 enzyme of peroxisomal beta-oxidation (eg, pseudo–NALD, pseudo-ZWS, bifunctional protein insufficiency); and disorders displaying the ZWS phenotype characterized by the loss of several enzymes and a normal amount of peroxisomes. In ZWS-like syndrome, enzymes for peroxisomal beta-oxidation are still unidentified.
Group 2 contains the RCDPs and related bone dysplasias. RCDP types II and III are due to plasmalogen deficiency.
Group 3 includes the X-ALD and phenotypic variants.
Group 4 comprises hyperoxaluria, acatalasemia, Refsum's disease, mevalonate kinase deficiency, glutaryl-CoA oxidase deficiency, and dihydroxy or trihydroxy cholestanoic acidemia (enzyme unknown).
Two-group classification based on organelle structure and deficiencies
Although different classifications have been proposed, the growing consensus supports a classification in which 2 groups of disorders are distinguished: (1) disorders of peroxisomal biogenesis (PBD) in which the organelle is abnormally formed and missing several functions and (2) single-enzyme deficiencies with intact peroxisomal structure.
The second group includes at least 10 disorders in which the defect involves a single peroxisomal protein but the structure of the peroxisome is intact. This category includes ALD (ie, VLCFA synthesis deficiency), AMN, pseudo–neonatal ALD (ie, NALD, or acyl-CoA oxidase deficiency), metabolic kinase deficiency, hyperoxaluria type I (ie, alanine glyoxylate aminotransferase deficiency), bifunctional enzyme deficiency, pseudo-ZWS (ie, peroxisome thiolase deficiency), acatalasemia (ie, catalase deficiency), dihydroxy acetone phosphate (DHAP) acyltransferase (AT) deficiency (ie, DHAP-AT deficiency, or type II rhizomelic chondrodysplasia punctata [RCPD]), alkyl-DHAP synthase deficiency (ie, type III RCDP), glutaric aciduria type III, and classic Refsum disease (ie, phytanoyl-CoA hydroxylase deficiency).
PDBs are due to mutation or mutations in the PEX genes that normally encode for peroxin proteins and whose proper expression is required for peroxisome biogenesis. Fourteen distinct PEX genes have been described.
- Zellweger syndrome
- ZWS is considered to be the prototype of the PBD group, which includes NALD, IRD, and HPA. Bowen et al first described ZWS in 1964. Passarge and McAdams introduced the name cerebrohepatorenal syndrome.
- ZWS causes multiple congenital anomalies dominated by a typical craniofacial dysmorphism, including a high forehead, a large anterior fontanelle, hypoplastic supraorbital ridges, broad nasal bridge, micrognathia, deformed ear lobes, and redundant nuchal skin folds.
- The neurologic picture comprises severe psychomotor retardation, profound hypotonia with depressed deep tendon reflexes (DTRs), neonatal seizures, and impaired hearing. Brain anomalies include cortical dysplasia with pachygyria and neuronal heterotopia; regressive changes related to storage with subsequent cell death may be seen. Dysmyelination rather than demyelination is observed.
- Ocular findings include congenital cataract, glaucoma and retinal degeneration with an absent electroretinogram (ERG).
- Other abnormalities are calcific stippling of the epiphyses, small renal cysts, and liver cirrhosis.
- Patients with ZWS have a decreased number of hepatic peroxisomes, impaired plasmalogen synthesis (especially in RBCs) and increased levels of VLCFA, bile acids, pipecolic, and phytanic acids. These findings suggest the involvement of different peroxisomal pathways.
- Patients with NALD and IRD have less severe disease and longer survival rates than those of patients with ZWS. Sensorineural hearing loss and pigmentary retinal degeneration is invariably present. Leukodystrophy may develop in the mild phenotypes; however, migration defects are not common, and seizures are usually absent in IRD but not in NALD, which involves exclusive atrophy of the adrenal cortex. Likewise, renal cysts and chondrodysplasia punctata are not typically present. However, short stature and delayed eruption of teeth are noted.
- HPA is considered to belong to the PBD group; however, isolated HPA is rare and not well understood.
- Zellweger syndrome
Rhizomelic chondrodysplasia punctata 1
- RCDP type 1 is a heterogenous group of disorders that is clinically distinct from the ZWS.
- Various forms of inheritance with autosomal or X-linked, dominant, or recessive patterns have been described.
- Peroxisomal abnormalities are found in only the rhizomelic autosomal recessive variant. Patients with these abnormalities have short stature, with spasticity and contractures, dysmorphic facies, and severe mental retardation. Shortening mainly involves the proximal parts of the limbs. Patients suffer mostly from severe scoliosis and chronic chest infection. Skeletal radiography typically reveals bone dysplasia with epiphyseal stippling. Death occurs in the first decade of life. Plasmalogen deficiency is a consistent feature and highly reliable for diagnosis.
Single-enzyme deficiencies with intact peroxisomal structure include disorders of peroxisomal beta-oxidation (POD), disorders of ether-phospholipid biosynthesis, and disorders of fatty acid alpha-oxidation.
- Disorders of peroxisomal beta-oxidation - X-ALD
- These disorders, seen only in males, are due to mutations in the ABCD1 gene. This gene encodes for ABC, a transporter molecule involved in the uptake of VLCFA across peroxisomal membranes. This mutation results in the accumulation of VLCFA due to lack of peroxisomal oxidation. Clinical presentations are diverse, ranging from the lethal cerebral childhood form to an isolated Addison-like disease with no neurologic involvement. Phenotypes in the same pedigree are markedly heterogeneous, a phenomenon attributed to the action of a possible modifier gene.
- Semmler et al have suggested that polymorphisms of genes involved in methionine metabolism modify phenotype in X-ALD, and have found evidence that the Tc2 genotype contributes to X-ALD phenotype generation.
- Approximately 20% of women who are heterozygous for the ALD locus develop neurologic disability that is milder and later in onset than that observed in affected men. Deficits vary from mild hyperreflexia and vibratory sense impairment to paraparesis causing patients to use a wheelchair. Signs of dementia are rare. The implicated gene is subject to X-inactivation.
- In the cerebral form of X-ALD, early development is entirely normal, and the first neurologic manifestations most commonly occur at 4-8 years of age. Asymptomatic boys may have a normal full-scale IQ but a low performance IQ. Early manifestations are often mistaken for attention-deficit/hyperactivity disorder. Characteristic neurologic manifestations, such as impaired auditory discrimination, visual disturbances, spatial disorientation, poor coordination, and seizures supervene later in the disease, which may then progress rapidly. Progression leads to a vegetative state in 2 years and death at some point thereafter. Relatively uncommon adolescent and adult cerebral forms can occur. An inflammatory response is seen in the cerebral form.
- AMN, another variant of X-ALD, causes slowly progressive paraparesis and sphincter disturbances and is often misdiagnosed as multiple sclerosis. Symptoms typically start at 28 ± 9 years. Forms include pure AMN and AMN-cerebral. Patients with pure AMN present with only spinal cord and peripheral nerve involvement and sparing of higher cognitive functions. However, neuropsychological testing may show subtle deficits in psychomotor speed and visual memory. This variant has a better prognosis than that of other forms. AMN-cerebral is used to describe increased impairment of neuropsychological function. Patients have various degrees of brain MRI abnormalities.
- Progressive cerebellar disorder resembling olivopontocerebellar degeneration is described.
- The Addison-like phenotype is distinguished from Addison disease by high levels of serum VLCFA.
- Patients with acyl-CoA oxidase deficiency, or pseudo-NALD, have a ZWS phenotype but no dysmorphic features. Symptoms consist of hypotonia, psychomotor regression, seizures, deafness and retinopathy with hypodensity of the cerebral white matter in addition to adrenocortical insufficiency. However, all peroxisomal metabolites, for the exception of VLCFA, are normal.
- D-Bifunctional protein deficiency results in a phenotype similar to that of ZWS, with dysmorphic facies and cerebral migrational defects. levels of both VLCFA and bile-acid intermediates are abnormally elevated. However, peroxisomes appear normal on liver biopsy.
- Peroxisomal thiolase deficiency, or pseudo-ZWS, is believed to be a subgroup of D-bifunctional protein deficiency.
- Peroxisomal 2-methylacyl-CoA racemase deficiency (AMACR) is characterized by a defect in beta-oxidation of branched-chain fatty acids. Clinical manifestations consist of adult-onset sensory-motor neuropathy, a symptom also reported in Refsum disease and in the ALD variant. However, phytanic acid and VLCFA levels are normal, though levels of 2-methyl branched-chain fatty acid, pristanic acid, and DHCA and/or THCA are abnormally elevated. Symptoms may vary, and patients may have isolated liver disease without neurologic involvement.
- Disorders of ether-phospholipid biosynthesis
- In most patients with RCDP type I, the primary defect involves the PEX-7 gene, which encodes for the peroxisomal targeting sequence (PTS-2) receptor. This receptor helps to target cytosolic proteins to the peroxisome. As a result, multiple peroxisomal enzymes that depend on PTS-2 signaling are affected (eg, peroxisomal thiolase, alkyl DHAP synthase, phytanoyl-CoA hydroxylase, DHAP-AT).
- RCDP types II and III are characterized by variable severity of clinical manifestations and by disproportionately short stature that primarily affects the proximal parts of the extremities, a typical facial appearance, congenital contractures, cataracts, and mental retardation similar to that of RCDP type I. However, bone stippling is not present. In RCDP types II and III, the PEX-7 protein is normal, and a mutation occurs in the structural gene encoding for their specific enzymes, PHAP-AT and alkyl DHAP synthase, respectively. Plasmalogen is deficient but, unlike RCDP type I, phytanic acid and other peroxisomal metabolites are normal.
- Mevalonate kinase is implicated in the biosynthesis of isoprenoids. Its deficiency leads to elevated levels of mevalonic acid in the urine. Clinical manifestations include developmental delay, cataracts, hepatosplenomegaly, and lymphadenopathy with early death. Similar symptoms have been observed in patients with hypergammaglobulinemia type D and periodic fever syndrome in addition to skin rash and arthralgias.
- Acatalasemia is a rare disease variably associated with catalase deficiency and ulcerating oral lesions. It has been described in Japan and in Switzerland.
- Mulibrey nanism, also known as muscle-liver-brain-eye syndrome, has been described in Finnish people and consists of muscle weakness, constrictive pericarditis, hepatomegaly, and J -shaped sella turcica with enlarged cerebral ventricles. Yellowish dots are noted on funduscopic examination. Patients have severe growth retardation but normal psychomotor development. Plasma VLCFA and liver peroxisomes are normal. The protein involved is strongly suspected but not yet confirmed to be a peroxisomal factor.
- Patients with hyperoxaluria type I due to deficiency of the liver peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. Calcium oxalate urolithiasis and nephrocalcinosis is present that leads to progressive renal failure at various ages. In addition, they may develop myocarditis, neuropathy, osteosclerosis, and retinopathy as a result of oxalate deposits in various organs. Urine excretion of glyoxylic and glycolic acid is increased. The enzyme is present only in the liver, and liver biopsy is usually needed for diagnosis.
- Disorders of fatty acid alpha-oxidation: Refsum disease is the only known type in this group. It is characterized by retinitis pigmentosa, sensory-motor polyneuropathy, cerebellar ataxia, and elevated cerebrospinal fluid protein levels without pleocytosis. Other features include sensory-neural hearing loss, anosmia, ichthyosis, skeletal malformation and cardiac abnormalities. Accumulation of phytanic acid in brain, blood, and other tissues is toxic.
- Disorders of peroxisomal beta-oxidation - X-ALD
Wanders RJ. Peroxisomes, lipid metabolism, and human disease. Cell Biochem Biophys. 2000. 32 Spring:89-106. [Medline].
Wanders RJ, Ferdinandusse S, Brites P, Kemp S. Peroxisomes, lipid metabolism and lipotoxicity. Biochim Biophys Acta. 2010 Mar. 1801(3):272-80. [Medline].
Baumgartner MR, Poll-The BT, Verhoeven NM, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov. 44(5):720-30. [Medline].
Bowen P, Lee CS, Zellweger H, Lindenberg R. A Familial Syndrome of Multiple Congenital Defects. Bull Johns Hopkins Hosp. 1964 Jun. 114:402-14. [Medline].
Kemp S, Wanders RJ. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol Genet Metab. 2007 Mar. 90(3):268-76. [Medline].
Semmler A, Bao X, Cao G, Köhler W, Weller M, Aubourg P, et al. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. J Neurol. 2009 Aug. 256(8):1277-80. [Medline].
Kaga M, Furushima W, Inagaki M, Nakamura M. Early neuropsychological signs of childhood adrenoleukodystrophy (ALD). Brain Dev. 2009 Aug. 31(7):558-61. [Medline].
Hubbard WC, Moser AB, Liu AC, Jones RO, Steinberg SJ, Lorey F, et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab. 2009 Jul. 97(3):212-20. [Medline].
U.S. Food and Drug Administration (press release). FDA approves Cholbam to treat rare bile acid synthesis disorders. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm438572.htm. Accessed: 2015 Mar 24.
Cholbam (cholic acid) [package insert]. Baltimore, MD: Asklepion Pharmaceuticals LLC. 2015 Mar. Available at [Full Text].
Zolotov D, Wagner S, Kalb K, et al. Long-term strategies for the treatment of Refsum's disease using therapeutic apheresis. J Clin Apher. 2012. 27(2):99-105. [Medline].
Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009 Nov 6. 326(5954):818-23. [Medline].
Boelens JJ, Prasad VK, Tolar J, Wynn RF, Peters C. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am. 2010 Feb. 57(1):123-45. [Medline].
Martinez M, Pineda M, Vidal R, et al. Docosahexaenoic acid--a new therapeutic approach to peroxisomal-disorder patients: experience with two cases. Neurology. 1993 Jul. 43(7):1389-97. [Medline].
Noguer MT, Martinez M. Visual Follow-Up In Peroxisomal-Disorder Patients Treated With Docosahexaenoic Acid Ethyl Ester. Invest Ophthalmol Vis Sci. 2009 Nov 20. [Medline].
Engelen M, Tran L, Ofman R, Brennecke J, Moser AB, Dijkstra IM. Bezafibrate for x-linked adrenoleukodystrophy. PLoS One. 2012. 7(7):e41013. [Medline].
al-Essa M, Dhaunsi GS, Rashed M, et al. Zellweger syndrome in Saudi Arabia and its distinct features. Clin Pediatr (Phila). 1999 Feb. 38(2):77-86. [Medline].
Aubourg P, Blanche S, Jambaque I, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med. 1990 Jun 28. 322(26):1860-6. [Medline].
Baes M, Gressens P, Baumgart E, et al. A mouse model for Zellweger syndrome. Nat Genet. 1997 Sep. 17(1):49-57. [Medline].
Barker PB, Horska A. Neuroimaging in leukodystrophies. J Child Neurol. 2004 Aug. 19(8):559-70. [Medline].
Barth PG, Majoie CB, Gootjes J, et al. Neuroimaging of peroxisome biogenesis disorders (Zellweger spectrum) with prolonged survival. Neurology. 2004 Feb 10. 62(3):439-44. [Medline].
Braverman N, Steel G, Obie C, et al. Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nat Genet. 1997 Apr. 15(4):369-76. [Medline].
Breitling R. Pathogenesis of peroxisomal deficiency disorders (Zellweger syndrome) may be mediated by misregulation of the GABAergic system via the diazepam binding inhibitor. BMC Pediatr. 2004 Mar 12. 4:5. [Medline].
Dimmick JE, Applegarth DA. Pathology of peroxisomal disorders. Perspect Pediatr Pathol. 1993. 17:45-98. [Medline].
Edwin D, Speedie LJ, Kohler W, et al. Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy. Ann Neurol. 1996 Oct. 40(4):675-8. [Medline].
Esiri MM, Hyman NM, Horton WL, Lindenbaum RH. Adrenoleukodystrophy: clinical, pathological and biochemical findings in two brothers with the onset of cerebral disease in adult life. Neuropathol Appl Neurobiol. 1984 Nov-Dec. 10(6):429-45. [Medline].
Ferri R, Chance PF. Lorenzo's oil: advances in the treatment of neurometabolic disorders. Arch Neurol. 2005 Jul. 62(7):1045-6. [Medline].
Gartner J, Braun A, Holzinger A , et al. Clinical and genetic aspects of X-linked adrenoleukodystrophy. Neuropediatrics. 1998 Feb. 29(1):3-13. [Medline].
Gilles L, Adams R, Kolony E. The neurology of neonatal hereditary metabolic diseases. In: Neurology of Hereditary Metabolic Diseases of Children. New York, NY: McGraw Hill;. 1996: 6-44.
Griffin DE, Moser HW, Mendoza Q, et al. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol. 1985 Dec. 18(6):660-4. [Medline].
Jaffe R, Crumrine P, Hashida Y, Moser HW. Neonatal adrenoleukodystrophy: clinical, pathologic, and biochemical delineation of a syndrome affecting both males and females. Am J Pathol. 1982 Jul. 108(1):100-11. [Medline].
Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet. 1997 Oct. 17(2):190-3. [Medline].
Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet. 1997 Oct. 17(2):190-3. [Medline].
Jansen GA, Wanders RJ, Watkins PA,, Mihalik SJ. Phytanoyl-coenzyme A hydroxylase deficiency -- the enzyme defect in Refsum's disease. N Engl J Med. 1997 Jul 10. 337(2):133-4. [Medline].
Kaufmann WE, Theda C, Naidu S, et al. Neuronal migration abnormality in peroxisomal bifunctional enzyme defect. Ann Neurol. 1996 Feb. 39(2):268-71. [Medline].
Kelley RI, Datta NS, Dobyns WB, et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet. 1986 Apr. 23(4):869-901. [Medline].
Knazek RA, Rizzo WB, Schulman JD, Dave JR. Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. J Clin Invest. 1983 Jul. 72(1):245-8. [Medline].
Kruse B, Barker PB, van Zijl PC, et al. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol. 1994 Oct. 36(4):595-608. [Medline].
Kumar AJ, Rosenbaum AE, Naidu S, et al. Adrenoleukodystrophy: correlating MR imaging with CT. Radiology. 1987 Nov. 165(2):497-504. [Medline].
Lu JF, Lawler AM, Watkins PA, et al. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A. 1997 Aug 19. 94(17):9366-71. [Medline].
MacDonald JT, Stauffer AE, Heitoff K. Adrenoleukodystrophy: early frontal lobe involvement on computed tomography. J Comput Assist Tomogr. 1984 Feb. 8(1):128-30. [Medline].
McDonald JC, Landreneau MD, Rohr MS, DeVault GA Jr. Reversal by liver transplantation of the complications of primary hyperoxaluria as well as the metabolic defect. N Engl J Med. 1989 Oct 19. 321(16):1100-3. [Medline].
Migeon BR, Moser HW, Moser AB, et al. Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A. 1981 Aug. 78(8):5066-70. [Medline].
Mihalik SJ, Morrell JC, Kim D, et al. Identification of PAHX, a Refsum disease gene. Nat Genet. 1997 Oct. 17(2):185-9. [Medline].
Moser HW, Moser AB. Peroxisomal disorders: overview. Ann N Y Acad Sci. 1996 Dec 27. 804:427-41. [Medline].
Moser HW, Naidu S, Kumar AJ, Rosenbaum AE. The adrenoleukodystrophies. Crit Rev Neurobiol. 1987. 3(1):29-88. [Medline].
Moser HW, Raymond GV, Lu SE, et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol. 2005 Jul. 62(7):1073-80. [Medline].
Mosser J, Douar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature. 1993 Feb 25. 361(6414):726-30. [Medline].
Mosser J, Lutz Y, Stoeckel ME, et al. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet. 1994 Feb. 3(2):265-71. [Medline].
Ofman R, Hettema EH, Hogenhout EM, et al. Acyl-CoA:dihydroxyacetonephosphate acyltransferase: cloning of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2. Hum Mol Genet. 1998 May. 7(5):847-53. [Medline].
Poll-The BT, Roels F, Ogier H, et al. A new peroxisomal disorder with enlarged peroxisomes and a specific deficiency of acyl-CoA oxidase (pseudo-neonatal adrenoleukodystrophy). Am J Hum Genet. 1988 Mar. 42(3):422-34. [Medline].
Powers J. Peroxisomal diseases. In: Pediatric Neuropathology. Baltimore, Md: Lippincott Williams & Wilkins;. 1995: 630-9.
Powers JM. Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex). Clin Neuropathol. 1985 Sep-Oct. 4(5):181-99. [Medline].
Powers JM. The pathology of peroxisomal disorders with pathogenetic considerations. J Neuropathol Exp Neurol. 1995 Sep. 54(5):710-9. [Medline].
Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol. 1992 Nov. 51(6):630-43. [Medline].
Powers JM, Moser HW. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol. 1998 Jan. 8(1):101-20. [Medline].
Powers JM, Schaumburg HH, Johnson AB, Raine CS. A correlative study of the adrenal cortex in adreno-leukodystrophy--evidence for a fatal intoxication with very long chain saturated fatty acids. Invest Cell Pathol. 1980 Oct-Dec. 3(4):353-76. [Medline].
Powers JM, Tummons RC, Caviness VS, et al. Structural and chemical alterations in the cerebral maldevelopment of fetal cerebro-hepato-renal (Zellweger) syndrome. J Neuropathol Exp Neurol. 1989 May. 48(3):270-89. [Medline].
Purdue PE, Zhang JW, Skoneczny M, Lazarow PB. Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor. Nat Genet. 1997 Apr. 15(4):381-4. [Medline].
Roth KS. Peroxisomal disease--common ground for pediatrician, cell biologist, biochemist, pathologist, and neurologist. Clin Pediatr (Phila). 1999 Feb. 38(2):73-5. [Medline].
Schram AW, Goldfischer S, van Roermund CW, et al. Human peroxisomal 3-oxoacyl-coenzyme A thiolase deficiency. Proc Natl Acad Sci U S A. 1987 Apr. 84(8):2494-6. [Medline].
Volpe JJ, Adams RD. Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration. Acta Neuropathol (Berl). 1972. 20(3):175-98. [Medline].
Wanders RJ. Metabolic and molecular basis of peroxisomal disorders: a review. Am J Med Genet A. 2004 May 1. 126(4):355-75. [Medline].
Wanders RJ. Peroxisomal disorders: clinical, biochemical, and molecular aspects. Neurochem Res. 1999 Apr. 24(4):565-80. [Medline].
Wanders RJ. Peroxisomes, lipid metabolism, and peroxisomal disorders. Mol Genet Metab. 2004 Sep-Oct. 83(1-2):16-27. [Medline].
Wanders RJ, Schutgens RB, Barth PG. Peroxisomal disorders: a review. J Neuropathol Exp Neurol. 1995 Sep. 54(5):726-39. [Medline].
Wanders RJ, Waterham HR. Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders. Clin Genet. 2005 Feb. 67(2):107-33. [Medline].
Watts RW, Morgan SH, Danpure CJ, et al. Combined hepatic and renal transplantation in primary hyperoxaluria type I: clinical report of nine cases. Am J Med. 1991 Feb. 90(2):179-88. [Medline].
Yakovac WC. Calcareous chondropathies in the newborn infant. AMA Arch Pathol. 1954 Jan. 57(1):62-79. [Medline].
Young RS, Ramer JC, Towfighi J, et al. Adrenoleukodystrophy: unusual computed tomographic appearance. Arch Neurol. 1982 Dec. 39(12):782-3. [Medline].